• linkedin
  • Increase Font
  • Sharebar

    Bladder Ca guide provides risk-stratified framework

    Document emphasizes importance of documenting tumor size, configuration

    San Diego—A recently released guideline on diagnosis and treatment of nonmuscle-invasive bladder cancer (NMIBC) from the AUA and the Society of Urologic Oncology provides practitioners with a risk-stratified clinical framework to aid treatment decisions and surveillance strategies, said Sam S. Chang, MD, MBA.

    More on Bladder Ca: What anti-PD-L1 immunotherapy approval means for urology

    Sam S. Chang, MD, MBADr. ChangDr. Chang, chair of the NMIBC guideline panel, presented highlights during a plenary session at the AUA annual meeting in San Diego.  

    “In an attempt to avoid a one-size-fits-all strategy, we wanted to take into account that the risk of recurrence and/or progression of NMIBC depends on several clinical and pathologic factors, and so we tried to personalize treatment choices and follow-up protocols,” said Dr. Chang, professor of urologic surgery and oncology, Vanderbilt University Medical Center, Nashville, TN.

    Also see: Genetics of two bladder cancer variants analyzed

    The guideline, which includes 38 statements, was developed based on a weighted review of data. It uses a risk stratification system that builds on schemes from the European Organization for Research and Treatment of Cancer and the Spanish Urological Club for Oncological Treatment by incorporating lymphovascular invasion, prostatic urethral involvement, variant histologies, and response to bacillus Calmette–Guérin (BCG). The risk-stratified treatment recommendations are summarized in an easy-to-follow flow chart.

    Next: Evaluation and diagnosis


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available